Anti-c5 antibodies and uses thereof

Abstract

The present invention provides monoclonal antibodies that bind to the complement factor 5 (C5) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to C5 protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing C5 activity, thus providing a means of treating or preventing a C5-related disease or disorder in humans. In some embodiments, the invention provides for an anti-C5 antibody that has improved pharmacokinetic and pharmacodynamic properties, e.g., a half-life of more than 10 days.

1 .- 40 . (canceled) 
     
     
         41 . A method for making an antibody or antigen-binding fragment thereof that binds specifically to C5 comprising:
 a heavy chain variable region (HCVR) that comprises a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 100; a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 102; and a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 104;   and a light chain variable region (LCVR) that comprises a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence set forth in SEQ ID NO: 108; a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence set forth in SEQ ID NO: 110; and a light chain complementarity determining region 3 (LCDR3) comprising the amino acid sequence set forth in SEQ ID NO: 112;   wherein the method comprises culturing a host cell comprising one or more polynucleotides encoding the HCVR and LCVR of the antibody or antigen-binding fragment under conditions permitting production of the antibody or antigen-binding fragment.   
     
     
         42 . The method of  claim 41 , further comprising recovering the antibody or antigen-binding fragment from the host cell. 
     
     
         43 . The method of  claim 41 , wherein the antibody or antigen-binding fragment comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 98; and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 106. 
     
     
         44 . The method of  claim 41 , wherein the antibody or antigen-binding fragment comprises a heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 353. 
     
     
         45 . The method of  claim 41 , wherein the antibody or antigen-binding fragment comprises a light chain comprising an amino acid sequence of SEQ ID NO: 354. 
     
     
         46 . The method of  claim 41 , wherein the antibody or antigen-binding fragment comprises a heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 353; and a light chain comprising an amino acid sequence set forth in SEQ ID NO: 354. 
     
     
         47 . The method of  claim 41 , wherein the one or more polynucleotides encoding the HCVR and LCVR comprise:
 a nucleotide sequence as set forth in SEQ ID NO: 99,   a nucleotide sequence as set forth in SEQ ID NO: 101,   a nucleotide sequence as set forth in SEQ ID NO: 103,   a nucleotide sequence as set forth in SEQ ID NO: 107,   a nucleotide sequence as set forth in SEQ ID NO: 109, and   a nucleotide sequence as set forth in SEQ ID NO: 111.   
     
     
         48 . The method of  claim 41 , wherein the one or more polynucleotides encoding the HCVR and LCVR comprise a nucleotide sequence as set forth in SEQ ID NO: 97. 
     
     
         49 . The method of  claim 41 , wherein one or more polynucleotides encoding the HCVR and LCVR comprise a nucleotide sequence as set forth in SEQ ID NO: 105. 
     
     
         50 . The method of  claim 41 , wherein the one or more polynucleotides encoding the HCVR and LCVR comprise a nucleotide sequence as set forth in SEQ ID NO: 97 and a nucleotide sequence as set forth in SEQ ID NO: 105. 
     
     
         51 . The method of  claim 41 , wherein the host cell is a Chinese hamster ovary (CHO) cell.